{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:45:53Z","timestamp":1791942353485,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11060-026-05830-x","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:45:19Z","timestamp":1791924319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma"],"prefix":"10.1007","volume":"180","author":[{"given":"Flavio","family":"Donnini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Pastina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Chibbaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Cerase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pasqualetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pascucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"D\u2019Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"5830_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5830_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5830_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"5830_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"5830_CR5","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G et al (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473\u20135480. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0774","journal-title":"Clin Cancer Res"},{"key":"5830_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-019-03146-7","volume":"143","author":"CY Hui","year":"2019","unstructured":"Hui CY, Rudra S, Ma S, Campian JL, Huang J (2019) Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients. J Neurooncol 143:129\u2013136. https:\/\/doi.org\/10.1007\/s11060-019-03146-7","journal-title":"J Neurooncol"},{"key":"5830_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-023-02393-3","volume":"19","author":"AM Saeed","year":"2024","unstructured":"Saeed AM, Bentzen SM, Ahmad H et al (2024) Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. Radiat Oncol 19:36. https:\/\/doi.org\/10.1186\/s13014-023-02393-3","journal-title":"Radiat Oncol"},{"key":"5830_CR8","doi-asserted-by":"publisher","first-page":"580101","DOI":"10.3389\/fneur.2020.580101","volume":"11","author":"CY Yang","year":"2020","unstructured":"Yang CY, Wen HB, Zhao YH, Huang WH, Wang ZF, Li ZQ (2020) Systemic inflammatory indicators as prognosticators in glioblastoma patients: a comprehensive meta-analysis. Front Neurol 11:580101. https:\/\/doi.org\/10.3389\/fneur.2020.580101","journal-title":"Front Neurol"},{"key":"5830_CR9","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.3390\/cancers15133339","volume":"15","author":"P Jarmuzek","year":"2023","unstructured":"Jarmuzek P et al (2023) Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 15:3339. https:\/\/doi.org\/10.3390\/cancers15133339","journal-title":"Cancers (Basel)"},{"key":"5830_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/neuonc\/noq001","volume":"12","author":"MP Gustafson","year":"2010","unstructured":"Gustafson MP, Lin Y, New KC et al (2010) Systemic immune suppression in glioblastoma: the interplay between CD14\u2009+\u2009HLA-DRlo\/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 12:631\u2013644. https:\/\/doi.org\/10.1093\/neuonc\/noq001","journal-title":"Neuro Oncol"},{"key":"5830_CR11","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet P, Jackson C, Koyama S et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24:1459\u20131468. https:\/\/doi.org\/10.1038\/s41591-018-0135-2","journal-title":"Nat Med"},{"key":"5830_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11060-026-05493-8","volume":"177","author":"F Roncelli","year":"2026","unstructured":"Roncelli F, Snider S, Boselli D et al (2026) Prognostic relevance and cytokine correlates of peripheral immune subpopulations in newly diagnosed glioblastoma. J Neurooncol 177:34. https:\/\/doi.org\/10.1007\/s11060-026-05493-8","journal-title":"J Neurooncol"},{"key":"5830_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11060-025-05302-8","volume":"176","author":"P Krupa","year":"2026","unstructured":"Krupa P, Kotek F, Krupova M, Paulikova S, Kasparova P, Cesak T (2026) Perioperative leukocyte\u2013plateletcrit shift as a prognostic signature in glioblastoma. J Neurooncol 176:27. https:\/\/doi.org\/10.1007\/s11060-025-05302-8","journal-title":"J Neurooncol"},{"key":"5830_CR14","doi-asserted-by":"publisher","first-page":"e13334","DOI":"10.1111\/bpa.13334","volume":"35","author":"B Asey","year":"2025","unstructured":"Asey B, Pantel TF, Mohme M et al (2025) Peripheral blood-derived immune cell counts as prognostic indicators and their relationship with DNA methylation subclasses in glioblastoma patients. Brain Pathol 35:e13334. https:\/\/doi.org\/10.1111\/bpa.13334","journal-title":"Brain Pathol"},{"key":"5830_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00262-024-03722-5","volume":"73","author":"L Hampe","year":"2024","unstructured":"Hampe L, Daumoine S, Limagne E et al (2024) Effect of radiochemotherapy on peripheral immune response in glioblastoma. Cancer Immunol Immunother 73:133. https:\/\/doi.org\/10.1007\/s00262-024-03722-5","journal-title":"Cancer Immunol Immunother"},{"key":"5830_CR16","doi-asserted-by":"publisher","first-page":"1343484","DOI":"10.3389\/fimmu.2024.1343484","volume":"15","author":"SA Dusoswa","year":"2024","unstructured":"Dusoswa SA, Verhoeff J, van Asten S et al (2024) The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment. Front Immunol 15:1343484. https:\/\/doi.org\/10.3389\/fimmu.2024.1343484","journal-title":"Front Immunol"},{"key":"5830_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387\u2013391. https:\/\/doi.org\/10.1038\/sj.bjc.6602678","journal-title":"Br J Cancer"},{"key":"5830_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-026-03964-3","author":"A Scafidi","year":"2026","unstructured":"Scafidi A, Kaoma T, Cerella C et al (2026) Circulating immune profiling reveals impaired monocyte states and trajectories driving immunosuppression in glioblastoma. J Neuroinflammation. https:\/\/doi.org\/10.1186\/s12974-026-03964-3","journal-title":"J Neuroinflammation"},{"key":"5830_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","volume":"139","author":"KL Pitter","year":"2016","unstructured":"Pitter KL, Tamagno I, Alikhanyan K et al (2016) Corticosteroids compromise survival in glioblastoma. Brain 139:1458\u20131471. https:\/\/doi.org\/10.1093\/brain\/aww046","journal-title":"Brain"},{"key":"5830_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/cancers16071393","volume":"16","author":"P Scheffler","year":"2024","unstructured":"Scheffler P, Fung C, Momjian S et al (2024) Dexamethasone in patients with glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 16:1393. https:\/\/doi.org\/10.3390\/cancers16071393","journal-title":"Cancers (Basel)"},{"key":"5830_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11060-026-05572-w","volume":"177","author":"C Friedes","year":"2026","unstructured":"Friedes C, Berger M, Linkowski L et al (2026) Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study. J Neurooncol 177:125. https:\/\/doi.org\/10.1007\/s11060-026-05572-w","journal-title":"J Neurooncol"},{"key":"5830_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","volume":"332","author":"DG Altman","year":"2006","unstructured":"Altman DG, Royston P (2006) The cost of dichotomising continuous variables. BMJ 332:1080. https:\/\/doi.org\/10.1136\/bmj.332.7549.1080","journal-title":"BMJ"},{"key":"5830_CR23","doi-asserted-by":"publisher","first-page":"e074819","DOI":"10.1136\/bmj-2023-074819","volume":"384","author":"GS Collins","year":"2024","unstructured":"Collins GS, Dhiman P, Ma J et al (2024) Evaluation of clinical prediction models (part 1): from development to external validation. BMJ 384:e074819. https:\/\/doi.org\/10.1136\/bmj-2023-074819","journal-title":"BMJ"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05830-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:04:54Z","timestamp":1791939894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05830-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5830"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05830-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"9 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Azienda Ospedaliero-Universitaria Senese, Area Vasta Sud-Est (protocol GLIOMARKERSOBS_2025-1; approved 6 May 2025) and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants according to institutional requirements.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"15"}}